Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
BPTH Bio-Path	$0.13 -5.3%	$0.16	$0.12 ▼ $3.39	$1.14M	-0.06	186,229 shs	3,220 shs
KRBP Kiromic BioPharma		$1.16	$0.16 ▼ $3.32	$330K	1.66	11,347 shs	107,749 shs
SLRX Salarius Pharmaceuticals	$0.46 +2.0%	$0.76	$0.43 ▼ $7.20	$960K	0.45	6.27 million shs	635,076 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BPTH Bio-Path	-5.31%	-7.00%	-17.07%	-29.62%	-91.38%
KRBP Kiromic BioPharma	0.00%	0.00%	0.00%	0.00%	-88.00%
SLRX Salarius Pharmaceuticals	+2.01%	-7.64%	-26.71%	-44.39%	-76.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	1.4698 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.0	1.3
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	0.1526 of 5 stars	0.0	2.0	0.0	0.0	2.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A
BPTH Bio-Path	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	($8.29) per share	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	($0.39) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
BPTH Bio-Path	-$16.08M	N/A	0.00	N/A	N/A	N/A	-2,842.40%	-337.48%	8/21/2025 (Estimated)
KRBP Kiromic BioPharma	-$26.90M	-$3.50	N/A	N/A	N/A	N/A	N/A	-277.46%	N/A
SLRX Salarius Pharmaceuticals	-$5.58M	-$4.82	N/A	∞	N/A	N/A	-556.47%	-192.35%	N/A

Latest KRBP, ASLN, SLRX, and BPTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SLRX Salarius Pharmaceuticals	-$2.20	-$0.45	+$1.75	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
BPTH Bio-Path	N/A	0.86	0.86
KRBP Kiromic BioPharma	N/A	0.16	0.22
SLRX Salarius Pharmaceuticals	N/A	0.61	1.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
BPTH Bio-Path	5.74%
KRBP Kiromic BioPharma	10.91%
SLRX Salarius Pharmaceuticals	11.88%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
BPTH Bio-Path	0.72%
KRBP Kiromic BioPharma	20.59%
SLRX Salarius Pharmaceuticals	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
BPTH Bio-Path	10	8.31 million	5.73 million	Optionable
KRBP Kiromic BioPharma	60	1.57 million	1.22 million	Not Optionable
SLRX Salarius Pharmaceuticals	20	2.13 million	2.10 million	Not Optionable

KRBP, ASLN, SLRX, and BPTH Headlines

Recent News About These Companies

Salarius Pharmaceuticals Announces Reverse Stock Split

1 hour ago | msn.com

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

August 14 at 1:23 PM | finanznachrichten.de

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

August 14 at 8:30 AM | globenewswire.com

Salarius Pharmaceuticals Raises $3.8M Through Stock Sale

July 31, 2025 | msn.com

Salarius Pharmaceuticals Modifies Security Holders’ Rights

July 30, 2025 | msn.com

Salarius Pharmaceuticals stock soars after Nasdaq extends compliance deadline

July 29, 2025 | investing.com

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

July 14, 2025 | finance.yahoo.com

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

July 14, 2025 | globenewswire.com

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...

July 11, 2025 | morningstar.comM

Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance

July 10, 2025 | uk.investing.com

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 10, 2025 | finance.yahoo.com

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 9, 2025 | globenewswire.com

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards

June 18, 2025 | nasdaq.com

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches

April 27, 2025 | investing.com

Salarius Pharmaceuticals announces Langer to join SAB

April 17, 2025 | markets.businessinsider.com

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

April 16, 2025 | globenewswire.com

Salarius Pharmaceuticals sees cash runway through later part of 2Q25

March 26, 2025 | markets.businessinsider.com

Salarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last year

March 26, 2025 | markets.businessinsider.com

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

March 24, 2025 | finanznachrichten.de

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

March 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRBP, ASLN, SLRX, and BPTH Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 08/13/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Bio-Path NASDAQ:BPTH

$0.13 -0.01 (-5.31%)

As of 08/15/2025 02:19 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Salarius Pharmaceuticals NASDAQ:SLRX

$0.46 +0.01 (+2.01%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.45 -0.01 (-3.20%)

As of 08/15/2025 07:47 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time